Recent 8-K filings for INBP

• May 8, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M

  Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.

• February 11, 2026, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M

  Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.

• September 23, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k

  Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.

• April 21, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.02item 1.01item 2.03item 9.01

  Integrated BioPharma enters $4.5M PNC credit facility; replaces prior debt

  New $4M revolving line of credit and $500K convertible equipment line from PNC Bank (SOFR+250bps).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.50 · Most common event earnings

3 positive 3 negative 9 neutral

source · INBP on sec.gov